Madrigal Pharmaceuticals Inc (NQ: MDGL )

Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug

February 08, 2024

The company is looking to take on Eli Lilly's tirzepatide as both a shot and a pill for weight loss.

A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance.

Madrigal Pharmaceuticals Stock Shows Rising Relative Strength

February 06, 2024

Each of these companies has a big market in its sights.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

February 06, 2024

Via Benzinga

2 Rising Biotechs That Could Become the Next Novo Nordisk

January 29, 2024

Neither is doing well this year.

Analyst Ratings for Madrigal Pharmaceuticals

November 13, 2023

Via Benzinga

2 Risky Stocks With Massive Potential

October 17, 2023

This company is on the brink of a major breakthrough.

1 Beaten-Down Stock That Could Soar by 86%, According to Wall Street

September 20, 2023

They might perform well in 2024, but how will they do beyond that?

The Latest Analyst Ratings for Madrigal Pharmaceuticals

September 11, 2023

Via Benzinga

2 Stocks That Could Soar This Year: Are They Buys?

January 22, 2024

Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development

January 12, 2024

89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties.

Via Benzinga

3 Stocks That Could Be Monster Winners in 2024

December 30, 2023

Don't be surprised if these three stocks take off in the new year.

Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session

December 08, 2023

Shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) moved lower during Friday’s session following weak quarterly earnings.

Via Benzinga

These 2 Stocks Could Be About to Soar: Are They Buys?

December 07, 2023

One thing is for certain -- both of these companies are innovators.

These stocks just might have investors seeing double over the next few years.

Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money

November 30, 2023

New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes,...

Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?

November 21, 2023

Via Benzinga

Topics ETFs

Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating

November 17, 2023

Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86.

Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits.

The 3 Most Undervalued Biotech Stocks to Buy: November 2023

November 14, 2023

With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows:

10 Health Care Stocks Whale Activity In Today's Session

November 02, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session

October 19, 2023

Via Benzinga

Nike, Carnival And 3 Stocks To Watch Heading Into Friday

September 29, 2023

Via Benzinga

Nike, Carnival, Activision Blizzard, Madrigal Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today?

September 28, 2023

U.S. stocks traded higher with the Dow Jones gaining over 110 points on Thursday. The Dow traded up 0.35% to 33,666.34 while the NASDAQ rose 0.83% to 13,201.28.

Via Benzinga

Topics Stocks

Exposures US Equities

Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon.

September 27, 2023

It has a good shot at commercializing a drug to treat a common liver disease.

Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due...

Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease

September 21, 2023

Via Benzinga

Madrigal Pharmaceuticals Surges As Its NASH Treatment Toes The Long-Awaited Finish Line

September 13, 2023

The company is toeing the finish line with a NASH treatment, an area of medicine marked by failures.

Smucker, FuelCell Energy, Granite Ridge Resources And Other Big Stocks Moving Lower On Monday

September 11, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Monday. Here are some big stocks recording losses in today’s session. IHS Holding Limited (NYSE: IHS) shares fell 15.7% to...

Via Benzinga

Topics Stocks

Exposures US Equities

The 3 Best Biotech Stocks to Buy Now: September 2023

September 04, 2023

With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize.

Worries about biotech stocks are way overdone, so the sector should make a big comeback in the coming months.

3 Biotech Stocks That Wall Street Analysts Can’t Get Enough Of

August 30, 2023

A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride.

The 3 Most Promising Pharma Stocks to Own Now

August 30, 2023

NASH treatments are projected to be one of the most sought-after indications in the coming years.

3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?

August 23, 2023